Page 38 - MI-2-2

Microbes & Immunity Genetic therapy with HSV-1 vectors

doi: 10.1038/sj.cgt.7700135 38. Logvinoff C, Epstein AL. A novel approach for herpes
simplex virus type 1 amplicon vector production, using
27. Kaur A, Sanford HB, Garry D, et al. Ability of herpes simplex
virus vectors to boost immune responses to DNA vectors and the Cre-loxP recombination system to remove helper virus.
to protect against challenge by simian immunodeficiency Hum Gene Ther. 2001;12(2):161-167.
virus. Virology. 2007;357(2):199-214. doi: 10.1089/104303401750061221
doi: 10.1016/j.virol.2006.08.007 39. Saydam O, Glauser DL, Fraefel C. Construction and
28. Harrington KJ, Hingorani M, Tanay MA, et al. Phase packaging of herpes simplex virus/adeno-associated virus
I/II study of oncolytic HSV GM-CSF in combination (HSV/AAV) Hybrid amplicon vectors. Cold Spring Harb
with radiotherapy and cisplatin in untreated stage III/IV Protoc. 2012;2012(3):352-356.
squamous cell cancer of the head and neck. Clin Cancer Res. doi: 10.1101/pdb.prot068114
2010;16(15):4005-4015.
40. Brooks AI, Cory-Slechta DA, Bowers WJ, Murg SL, Federoff
doi: 10.1158/1078-0432.CCR-10-0196 HJ. Enhanced learning in mice parallels vector-mediated
29. Epstein AL. HSV-1-derived amplicon vectors: Recent nerve growth factor expression in hippocampus. Hum Gene
technological improvements and remaining difficulties-a Ther. 2000;11(17):2341-2352.
review. Mem Inst Oswaldo Cruz. 2009;104(3):399-410. doi: 10.1089/104303400750038453
doi: 10.1590/s0074-02762009000300002 41. Harvey BK, Chang CF, Chiang YH, et al. HSV amplicon
30. Epstein AL. HSV-1-based amplicon vectors: Design and delivery of glial cell line-derived neurotrophic factor
applications. Gene Ther. 2005;12 Suppl 1:S154-S158. is neuroprotective against ischemic injury. Exp Neurol.
2003;183(1):47-55.
doi: 10.1038/sj.gt.3302617
doi: 10.1016/s0014-4886(03)00080-3.
31. Wang S, Fraefel C, Breakefield X. HSV-1 amplicon vectors.
Methods Enzymol. 2002;346:593-603. 42. DeLuca NA, Schaffer PA. Activation of immediate-early,
early, and late promoters by temperature-sensitive and wild-
doi: 10.1016/s0076-6879(02)46079-x type forms of herpes simplex virus type 1 protein ICP4. Mol
32. Marconi P, Argnani R, Berto E, Epstein AL, Manservigi R. Cell Biol. 1985;5(8):1997-2008.
HSV as a vector in vaccine development and gene therapy. doi: 10.1128/mcb.5.8.1997-2008.1985
Adv Exp Med Biol. 2009;655:118-144.
43. Kaplitt MG, Makimura H. Defective viral vectors as agents
33. Ho DY. Amplicon-based herpes simplex virus vectors. for gene transfer in the nervous system. J Neurosci Methods.
Methods Cell Biol. 1994;43 Pt A:191-210. 1997;71(1):125-132.
doi: 10.1016/s0091-679x(08)60604-4. doi: 10.1016/s0165-0270(96)00132-x
34. Saeki Y, Fraefel C, Ichikawa T, Breakefield XO, Chiocca EA. 44. Wood MJ, Byrnes AP, Kaplitt MG, et al. Specific patterns of
Improved helper virus-free packaging system for HSV defective HSV-1 gene transfer in the adult central nervous
amplicon vectors using an ICP27-deleted, oversized HSV-1 system: Implications for gene targeting. Exp Neurol.
DNA in a bacterial artificial chromosome. Mol Ther. 1994;130(1):127-140.
2001;3(4):591-601.
doi: 10.1006/exnr.1994.1192
doi: 10.1006/mthe.2001.0294
45. Kaplitt MG, Pfaff DW. Viral vectors for gene delivery and
35. Zaupa C, Revol-Guyot V, Epstein AL. Improved packaging expression in the CNS. Methods. 1996;10(3):343-350.
system for generation of high-level noncytotoxic HSV-1
amplicon vectors using Cre-loxP site-specific recombination doi: 10.1006/meth.1996.0112
to delete the packaging signals of defective helper genomes. 46. Ho DY, Fink SL, Lawrence MS, et al. Herpes simplex virus
Hum Gene Ther. 2003;14(11):1049-1063. vector system: Analysis of its in vivo and in vitro cytopathic
doi: 10.1089/104303403322124774 effects. J Neurosci Methods. 1995;57(2):205-215.
36. Cuchet D, Potel C, Thomas J, Epstein AL. HSV-1 amplicon doi: 10.1016/0165-0270(94)00150-f
vectors: A promising and versatile tool for gene delivery. 47. Krisky DM, Wolfe D, Goins WF, et al. Deletion of multiple
Expert Opin Biol Ther. 2007;7(7):975-995. immediate-early genes from herpes simplex virus reduces
doi: 10.1517/14712598.7.7.975 cytotoxicity and permits long-term gene expression in
neurons. Gene Ther. 1998;5(12):1593-1603.
37. Kasai K, Saeki Y. DNA-based methods to prepare helper virus-
free herpes amplicon vectors and versatile design of amplicon doi: 10.1038/sj.gt.3300766
vector plasmids. Curr Gene Ther. 2006;6(3):303-314.
48. Krisky DM, Marconi PC, Oligino TJ, et al. Development of
doi: 10.2174/156652306777592081 herpes simplex virus replication-defective multigene vectors

Volume 2 Issue 2 (2025) 30 doi: 10.36922/mi.7947